---
title: "SEP-631 的第一階段試驗結果積極，顯示出劑量依賴性抑制皮膚風團形成，在每天 10 毫克劑量時完全抑制。205 個字符"
description: "新藥 SEP-631 顯示出對由 icatibant 引起的皮膚風團形成具有強效且劑量依賴的抑制作用。在每天服用 10 毫克的低劑量下，已實現完全抑制"
type: "news"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/277360762.md"
published_at: "2026-03-01T14:46:12.000Z"
---

# SEP-631 的第一階段試驗結果積極，顯示出劑量依賴性抑制皮膚風團形成，在每天 10 毫克劑量時完全抑制。205 個字符

> 新藥 SEP-631 顯示出對由 icatibant 引起的皮膚風團形成具有強效且劑量依賴的抑制作用。在每天服用 10 毫克的低劑量下，已實現完全抑制

新藥 SEP-631 顯示出對由 icatibant 引起的皮膚風團形成具有強效且劑量依賴的抑制作用。在每日服用 10 毫克的低劑量下，已實現完全抑制。

### Related Stocks

- [SEPN.US - Septerna](https://longbridge.com/zh-HK/quote/SEPN.US.md)
- [BBH.US - 生物科技 ETF - VanEck Vectors](https://longbridge.com/zh-HK/quote/BBH.US.md)
- [FBT.US - 紐交所高增長板生物技術指數 ETF - First Trust](https://longbridge.com/zh-HK/quote/FBT.US.md)
- [PBE.US - 動態生物技術與基因組 ETF - Invesco](https://longbridge.com/zh-HK/quote/PBE.US.md)
- [BIB.US - 2 倍做多納斯達克生物技術 ETF - ProShares](https://longbridge.com/zh-HK/quote/BIB.US.md)
- [XBI.US - 標普生物技術 ETF - SPDR](https://longbridge.com/zh-HK/quote/XBI.US.md)
- [IBB.US - 納斯達克生物科技指數 ETF - iShares Nasdaq](https://longbridge.com/zh-HK/quote/IBB.US.md)
- [XLV.US - 醫療業 ETF - SPDR](https://longbridge.com/zh-HK/quote/XLV.US.md)
- [SBIO.US - 醫藥突破 ETF - ALPS](https://longbridge.com/zh-HK/quote/SBIO.US.md)
- [IHE.US - 美國制藥 ETF - iShares](https://longbridge.com/zh-HK/quote/IHE.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Alumis Shares Phase 3 Psoriasis Details, Targets 2H NDA Filing at Oppenheimer Healthcare Conference | Alumis (NASDAQ:ALMS) executives presented Phase 3 psoriasis results for envudeucitinib at the Oppenheimer Healthcare Con | [Link](https://longbridge.com/zh-HK/news/277123919.md) |
| Protara falls after mid-stage trial data for lead asset in bladder cancer | Protara Therapeutics (TARA) shares fell approximately 22% following the release of interim data from a mid-stage trial f | [Link](https://longbridge.com/zh-HK/news/276778182.md) |
| Dror Ortho-Design, Inc. SEC 10-K Report | Dror Ortho-Design, Inc. has released its annual 10-K report, detailing its financial performance and strategic initiativ | [Link](https://longbridge.com/zh-HK/news/277226243.md) |
| Soleno Therapeutics reports FY profit for 2025 | Soleno Therapeutics reported a profitable FY 2025 with a net income of $20.9 million, driven by Q4 revenue of $91.7 mill | [Link](https://longbridge.com/zh-HK/news/276938001.md) |
| Delcath Q4 revenue rises 37%, beats estimates | Delcath Systems reported a 37% increase in Q4 revenue, surpassing analyst expectations with $20.73 million. Despite a ne | [Link](https://longbridge.com/zh-HK/news/277046688.md) |

---

> **免責聲明**：本文內容僅供參考，不構成任何投資建議。